How does semaglutide actually produce weight loss?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The native GLP-1 hormone is secreted by L-cells in the gut after eating, with a half-life of approximately two minutes. Semaglutide is structurally modified to resist enzymatic degradation, extending its half-life to roughly seven days and enabling once-weekly dosing.
The weight-loss effect operates through three distinct mechanisms. First, semaglutide slows gastric emptying — food remains in the stomach longer, producing prolonged satiety after meals. Second, it directly activates GLP-1 receptors in the hypothalamic appetite-regulation centers (particularly the arcuate nucleus), reducing hunger signaling and meal frequency. Third, it enhances glucose-dependent insulin secretion, which improves insulin sensitivity and reduces compensatory hyperphagia.
The net clinical effect, demonstrated in the STEP 1 trial (Wilding et al., 2021), was an average 14.9% reduction in body weight at 68 weeks in patients with obesity, compared to 2.4% in the placebo group. Importantly, the SELECT trial (Lincoff et al., 2023) extended these findings to cardiovascular outcomes — semaglutide reduced major adverse cardiovascular events by 20% in adults with overweight/obesity and established cardiovascular disease, independent of diabetes status.
Who is a good candidate for semaglutide?
FDA labeling for Wegovy specifies adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea). We also consider patients outside these strict criteria when clinically appropriate — for example, patients with metabolic syndrome features and a strong family history of cardiovascular disease.
The strongest candidates are patients who have made meaningful lifestyle changes (improved diet quality, consistent physical activity, adequate sleep) without achieving sustainable weight reduction. GLP-1 therapy is not a substitute for these behaviors — patients who skip the lifestyle work tend to lose more lean mass, regain weight faster after discontinuation, and report less satisfaction with their results.
Patients with type 2 diabetes are particularly strong candidates given the dual glycemic and weight-loss benefit. The SURPASS-2 head-to-head trial of semaglutide vs tirzepatide in patients with type 2 diabetes (Frias et al., 2021) demonstrated A1c reductions of 1.8% on semaglutide and 2.0–2.3% on tirzepatide — meaningful for diabetes control regardless of weight effect.
Who should not take semaglutide?
Absolute contraindications include personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN2), prior serious hypersensitivity to semaglutide or excipients, and active pregnancy. The MTC association is based on rodent data and a class-wide labeling caution rather than confirmed human signal, but it remains a hard contraindication.
Relative contraindications requiring case-by-case assessment include history of pancreatitis, severe gastroparesis, active gallbladder disease, and severe inflammatory bowel disease during a flare. Patients with eating disorders — particularly active bulimia or restrictive anorexia — should be evaluated by a mental-health professional before starting any GLP-1 therapy.
Pregnancy planning requires discontinuation at least 2 months before conception due to semaglutide's long half-life. We discuss this proactively with women of childbearing potential at every semaglutide visit.
How is the dose titrated, week by week?
The standard titration schedule from STEP 1 begins at 0.25 mg once weekly with four-week steps: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg/week. Most patients reach the 2.4 mg maintenance dose at week 17. Faster escalation produces more nausea and GI side effects; slower escalation reduces them substantially without compromising long-term weight loss.
We adjust titration pace based on individual tolerance. Patients reporting persistent nausea at a given step often benefit from holding that dose for an additional 2–4 weeks before escalating. Patients tolerating well may move on schedule. The target is steady, tolerable progress — not adherence to a calendar.
- 01Weeks 1–4: 0.25 mg / wk — Initiation dose — no weight-loss effect expected
- 02Weeks 5–8: 0.5 mg / wk
- 03Weeks 9–12: 1.0 mg / wk — Most patients see appetite changes by this point
- 04Weeks 13–16: 1.7 mg / wk
- 05Week 17+: 2.4 mg / wk maintenance
How do we preserve muscle mass during semaglutide therapy?
Studies of GLP-1 monotherapy consistently show that 20–40% of weight lost without intervention is lean mass — a clinically significant concern given the metabolic and functional cost of sarcopenia. Muscle preservation is a non-negotiable component of every semaglutide protocol we run.
Three interventions matter. First, protein intake: target 0.8–1.0 grams of protein per pound of goal body weight, distributed across 3–4 meals. Second, resistance training: at least 2 weighted sessions per week targeting major muscle groups, progressing over time. Third, adequate sleep — 7+ hours nightly preserves growth hormone and testosterone signaling that supports lean-mass retention.
We track lean mass through periodic body composition assessment (in-office InBody or referral DEXA) at baseline, 3 months, and 6 months. Patients losing disproportionate lean mass receive intensified protein and resistance-training coaching before continuing dose escalation.
What does the labwork schedule look like?
Baseline labs before starting include: comprehensive metabolic panel (CMP) for renal and hepatic function, lipid panel, hemoglobin A1c, TSH, lipase, and a pregnancy test for women of childbearing potential. Patients with known thyroid disease or family history of MTC undergo additional thyroid evaluation.
Follow-up labs repeat at 3 months and every 6 months thereafter. The most clinically informative trends are A1c (for diabetic and prediabetic patients), lipid changes, and renal function. We do not routinely repeat lipase unless clinical symptoms suggest pancreatitis — baseline elevations without symptoms are common and not predictive.
When can semaglutide be discontinued, and what happens if it is?
The honest answer is that most patients regain a substantial fraction of lost weight within 1–2 years of discontinuation. The STEP 4 trial showed that patients who reached week 20 on semaglutide and then switched to placebo regained approximately two-thirds of their lost weight by week 68. This is the central reality of GLP-1 weight-loss therapy: it is more analogous to insulin therapy for diabetes than to a time-limited intervention.
Most patients plan for long-term maintenance dosing rather than a defined endpoint. The lifestyle changes (protein, resistance training, sleep, nutrition quality) implemented during the active phase substantially reduce — but do not eliminate — regain after discontinuation. Some patients successfully transition to lower maintenance doses (1.0–1.7 mg/week) after a year of stable weight at the goal range.
For patients who do discontinue, we recommend a structured taper rather than abrupt cessation, intensified lifestyle support during the first 6 months, and clear plans for re-initiation if regain exceeds 5% of body weight.
How does semaglutide compare to tirzepatide for weight loss?
Tirzepatide is a dual GLP-1 + GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. The added GIP activation produces stronger weight loss in head-to-head data — SURMOUNT-1 (Jastreboff et al., 2022) showed -22.5% body weight at 72 weeks on the 15 mg tirzepatide dose, compared to STEP 1's -14.9% on semaglutide at 68 weeks. SURPASS-2 (Frias et al., 2021) confirmed superior weight loss for tirzepatide in patients with type 2 diabetes.
In real-world practice, the trade-offs are cost and cardiovascular outcome data. Semaglutide has the SELECT trial behind it — a confirmed 20% reduction in major cardiovascular events in obesity. Tirzepatide's SURMOUNT-MMO cardiovascular outcomes trial is ongoing; until results are published, semaglutide remains the GLP-1 agent with confirmed cardiovascular benefit.
We often start patients on semaglutide for cost reasons and switch to tirzepatide if results plateau, the patient has weight loss as the primary goal, or insurance/pricing favors the switch. Patients with established cardiovascular disease who are weight-loss candidates lean toward semaglutide for the SELECT-validated benefit unless tirzepatide is otherwise indicated.